410 related articles for article (PubMed ID: 30565382)
21. Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD: A Secondary Analysis of the SCORED Trial.
Sridhar VS; Bhatt DL; Odutayo A; Szarek M; Davies MJ; Banks P; Pitt B; Steg PG; Cherney DZI
Clin J Am Soc Nephrol; 2024 May; 19(5):557-564. PubMed ID: 38277468
[TBL] [Abstract][Full Text] [Related]
22. Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium-Glucose Cotransporter-2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes.
Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Al-Aly Z
J Am Heart Assoc; 2021 Jun; 10(11):e020237. PubMed ID: 34013739
[TBL] [Abstract][Full Text] [Related]
23. Effect of sodium-glucose cotransporter-2 inhibitors on continuous glucose monitoring metrics, as adjunctive to insulin in adults with type 1 diabetes mellitus: a meta-analysis of randomized controlled trials.
Popovic DS; Karakasis P; Koufakis T; Fragakis N; Papanas N; Mitrovic M; Gouveri E; Patoulias D
Metabolism; 2024 Apr; 153():155791. PubMed ID: 38232802
[TBL] [Abstract][Full Text] [Related]
24. Association of SGLT2is with cardiovascular and reproductive diseases: a meta-analysis based on 14 large-scale randomized trials.
Li L; Dong YH; Bai Y; Tang ZY; Deng YM; Wu Z; Li WY
Endocrine; 2024 Jun; 84(3):836-841. PubMed ID: 38030828
[TBL] [Abstract][Full Text] [Related]
25. Abrupt Decline in Estimated Glomerular Filtration Rate after Initiating Sodium-Glucose Cotransporter 2 Inhibitors Predicts Clinical Outcomes: A Systematic Review and Meta-Analysis.
Chuang MH; Tang YS; Chen JY; Pan HC; Liao HW; Chu WK; Cheng CY; Wu VC; Heung M
Diabetes Metab J; 2024 Mar; 48(2):242-252. PubMed ID: 38273790
[TBL] [Abstract][Full Text] [Related]
26. Kidney outcomes of SGLT2 inhibitors among older patients with diabetic kidney disease in real-world clinical practice: the Japan Chronic Kidney Disease Database Ex.
Kitaoka K; Yano Y; Nagasu H; Kanegae H; Chishima N; Akiyama H; Tamura K; Kashihara N
BMJ Open Diabetes Res Care; 2024 May; 12(3):. PubMed ID: 38816204
[TBL] [Abstract][Full Text] [Related]
27. Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Rigato M; Fadini GP; Avogaro A
Diabetes Obes Metab; 2023 Oct; 25(10):2963-2969. PubMed ID: 37402697
[TBL] [Abstract][Full Text] [Related]
28. Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.
Heerspink HJ; Desai M; Jardine M; Balis D; Meininger G; Perkovic V
J Am Soc Nephrol; 2017 Jan; 28(1):368-375. PubMed ID: 27539604
[TBL] [Abstract][Full Text] [Related]
29. Effect of canagliflozin in non-diabetic obese patients with albuminuria: A randomized, double-blind, placebo-controlled trial.
Greeviroj P; Puapatanakul P; Phannajit J; Takkavatakarn K; Kittanamongkolchai W; Boonchaya-Anant P; Katavetin P; Praditpornsilpa K; Eiam-Ong S; Susantitaphong P
Clin Nephrol; 2023 Nov; 100(5):224-230. PubMed ID: 37675488
[TBL] [Abstract][Full Text] [Related]
30. Albuminuria, serum creatinine, and estimated glomerular filtration rate as predictors of cardio-renal outcomes in patients with type 2 diabetes mellitus and kidney disease: a systematic literature review.
Norris KC; Smoyer KE; Rolland C; Van der Vaart J; Grubb EB
BMC Nephrol; 2018 Feb; 19(1):36. PubMed ID: 29426298
[TBL] [Abstract][Full Text] [Related]
31. Renal function deterioration in adult patients with type-2 diabetes.
Bramlage P; Lanzinger S; Hess E; Fahrner S; Heyer CHJ; Friebe M; Buschmann I; Danne T; Holl RW; Seufert J
BMC Nephrol; 2020 Jul; 21(1):312. PubMed ID: 32727401
[TBL] [Abstract][Full Text] [Related]
32. Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure.
Nakagaito M; Imamura T; Joho S; Ushijima R; Nakamura M; Kinugawa K
BMC Cardiovasc Disord; 2021 Jul; 21(1):347. PubMed ID: 34289813
[TBL] [Abstract][Full Text] [Related]
33. Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations.
Khoo CM; Deerochanawong C; Chan SP; Matawaran B; Sheu WH; Chan J; Mithal A; Luk A; Suastika K; Yoon KH; Ji L; Man NH; Pollock C
Diabetes Obes Metab; 2021 Feb; 23(2):299-317. PubMed ID: 33155749
[TBL] [Abstract][Full Text] [Related]
34. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis.
Fox CS; Matsushita K; Woodward M; Bilo HJ; Chalmers J; Heerspink HJ; Lee BJ; Perkins RM; Rossing P; Sairenchi T; Tonelli M; Vassalotti JA; Yamagishi K; Coresh J; de Jong PE; Wen CP; Nelson RG;
Lancet; 2012 Nov; 380(9854):1662-73. PubMed ID: 23013602
[TBL] [Abstract][Full Text] [Related]
35. SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis.
Mavrakanas TA; Tsoukas MA; Brophy JM; Sharma A; Gariani K
Sci Rep; 2023 Sep; 13(1):15922. PubMed ID: 37741858
[TBL] [Abstract][Full Text] [Related]
36. The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease: a systematic review and meta-analysis.
Ma C; Li X; Li W; Li Y; Shui F; Zhu P
Int Urol Nephrol; 2023 Dec; 55(12):3167-3174. PubMed ID: 37046125
[TBL] [Abstract][Full Text] [Related]
37. Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study.
Matsuba I; Kawata T; Iemitsu K; Asakura T; Amemiya H; Ishikawa M; Ito S; Kaneshiro M; Kanamori A; Kubota A; Shinoda K; Takai M; Takuma T; Takihata M; Takeda H; Tanaka K; Matsuzawa Y; Machimura H; Minagawa F; Minami N; Mokubo A; Miyakawa M; Terauchi Y; Tanaka Y
J Diabetes Investig; 2020 Sep; 11(5):1248-1257. PubMed ID: 32149469
[TBL] [Abstract][Full Text] [Related]
38. Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis.
Kristensen KB; Henriksen DP; Hallas J; Pottegård A; Lund LC
Diabetologia; 2021 Jul; 64(7):1563-1571. PubMed ID: 33715024
[TBL] [Abstract][Full Text] [Related]
39. Assessing the use of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and chronic kidney disease in tertiary care: a SwissDiab Study.
Hösli PS; Renström F; Laimer M; Cavelti-Weder C; Gastaldi G; Lehmann R; Brändle M
BMJ Open Diabetes Res Care; 2024 Jun; 12(3):. PubMed ID: 38901857
[TBL] [Abstract][Full Text] [Related]
40. Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Reduced.
Zannad F; Ferreira JP; Gregson J; Kraus BJ; Mattheus M; Hauske SJ; Butler J; Filippatos G; Wanner C; Anker SD; Pocock SJ; Packer M;
Eur J Heart Fail; 2022 Oct; 24(10):1829-1839. PubMed ID: 35711093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
